Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
Arbutus Biopharma ( NASDAQ:ABUS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.53m (down 77% from 1Q...
Insights into Arbutus Biopharma Corp's Q1 performance, including financial updates and progress in clinical trials.